T. Rowe Price Associates’s Applied Genetic Technologies Corporation AGTC Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q4
Sell
-108,680
Closed -$30K 3036
2022
Q3
$30K Sell
108,680
-153,375
-59% -$67K ﹤0.01% 2889
2022
Q2
$202K Hold
262,055
﹤0.01% 2603
2022
Q1
$280K Hold
262,055
﹤0.01% 2576
2021
Q4
$498K Sell
262,055
-10,100
-4% -$24.2K ﹤0.01% 2386
2021
Q3
$819K Hold
272,155
﹤0.01% 2145
2021
Q2
$1.06M Sell
272,155
-2,446
-0.9% -$10.1K ﹤0.01% 2057
2021
Q1
$1.39M Buy
274,601
+10,865
+4% +$56.4K ﹤0.01% 1882
2020
Q4
$1.08M Hold
263,736
﹤0.01% 1903
2020
Q3
$1.28M Hold
263,736
﹤0.01% 1700
2020
Q2
$1.46M Buy
263,736
+1,681
+0.6% +$7.7K ﹤0.01% 1638
2020
Q1
$860K Hold
262,055
﹤0.01% 1766
2019
Q4
$1.18M Hold
262,055
﹤0.01% 1819
2019
Q3
$1.09M Hold
262,055
﹤0.01% 1787
2019
Q2
$993K Sell
262,055
-46,945
-15% -$192K ﹤0.01% 1848
2019
Q1
$1.29M Sell
309,000
-16,444
-5% -$57.5K ﹤0.01% 1738
2018
Q4
$810K Hold
325,444
﹤0.01% 1895
2018
Q3
$2.38M Sell
325,444
-128,985
-28% -$565K ﹤0.01% 1576
2018
Q2
$1.68M Buy
454,429
+264,448
+139% +$1.22M ﹤0.01% 1640
2018
Q1
$731K Hold
189,981
﹤0.01% 1920
2017
Q4
$684K Hold
189,981
﹤0.01% 1961
2017
Q3
$750K Hold
189,981
﹤0.01% 1910
2017
Q2
$969K Sell
189,981
-35
-0% -$197 ﹤0.01% 1798
2017
Q1
$1.31M Hold
190,016
﹤0.01% 1700
2016
Q4
$1.78M Hold
190,016
﹤0.01% 1592
2016
Q3
$1.86M Buy
190,016
+35
+0% +$472 ﹤0.01% 1553
2016
Q2
$2.68M Hold
189,981
﹤0.01% 1474
2016
Q1
$2.66M Hold
189,981
﹤0.01% 1476
2015
Q4
$3.88M Hold
189,981
﹤0.01% 1455
2015
Q3
$2.5M Hold
189,981
﹤0.01% 1523
2015
Q2
$2.91M Sell
189,981
-18,254
-9% -$350K ﹤0.01% 1537
2015
Q1
$4.16M Sell
208,235
-155,622
-43% -$3.48M ﹤0.01% 1496
2014
Q4
$7.65M Buy
+363,857
New +$7.41M ﹤0.01% 1391

T. Rowe Price Associates's AGTC Position: Q4 2022 in Review

T. Rowe Price Associates sold out of Applied Genetic Technologies Corporation (AGTC) in Q4 2022, closing a stake of 108,680 shares — an estimated $30K sold.

T. Rowe Price Associates first reported a position in AGTC in Q4 2014 and held it in 32 quarters. The position peaked at $7.65M in Q4 2014. 0 funds tracked by Wall St. Rank hold AGTC as of Q4 2022.

  • T. Rowe Price Associates reported no remaining Applied Genetic Technologies Corporation position as of Q4 2022 after selling out during the quarter.
  • T. Rowe Price Associates sold 108,680 Applied Genetic Technologies Corporation shares in Q4 2022, an estimated $30K.
  • T. Rowe Price Associates first reported a position in Applied Genetic Technologies Corporation in Q4 2014 and held it in 32 quarters.
  • T. Rowe Price Associates's Applied Genetic Technologies Corporation position peaked at $7.65M in Q4 2014.
  • 0 funds tracked by Wall St. Rank held Applied Genetic Technologies Corporation as of Q4 2022.

Based on T. Rowe Price Associates's 13F filing for Q4 2022, filed 14 Feb 2023.